HeimSHTDF • OTCMKTS
add
Sinopharm Group Co Ltd
Við síðustu lokun
2,30 $
Dagbil
2,35 $ - 2,35 $
Árabil
1,97 $ - 2,94 $
Markaðsvirði
57,54 ma. HKD
Meðalmagn
132,00
V/H-hlutf.
-
A/V-hlutfall
-
Aðalkauphöll
HKG
Í fréttum
Fjármál
Rekstrarreikningur
Tekjur
Nettótekjur
| (CNY) | des. 2024info | Breyting á/á |
|---|---|---|
Tekjur | 144,89 ma. | -3,82% |
Rekstrarkostnaður | 6,44 ma. | 15,96% |
Nettótekjur | 1,67 ma. | -43,43% |
Hagnaðarhlutfall | 1,15 | -41,33% |
Hagnaður á hvern hlut | — | — |
EBITDA | 5,32 ma. | -35,75% |
Virkt skatthlutfall | 29,36% | — |
Efnahagsreikningur
Heildareignir
Heildarskuldir
| (CNY) | des. 2024info | Breyting á/á |
|---|---|---|
Reiðufé og skammtímafjárfestingar | 54,31 ma. | -19,10% |
Heildareignir | 392,83 ma. | 2,46% |
Heildarskuldir | 266,14 ma. | 1,17% |
Eigið fé alls | 126,69 ma. | — |
Útistandandi hlutabréf | 3,12 ma. | — |
Eiginfjárgengi | 0,09 | — |
Arðsemi eigna | 3,00% | — |
Ávöxtun eigin fjár | 5,81% | — |
Peningaflæði
Breyting á handbæru fé
| (CNY) | des. 2024info | Breyting á/á |
|---|---|---|
Nettótekjur | 1,67 ma. | -43,43% |
Handbært fé frá rekstri | 26,27 ma. | 43,57% |
Reiðufé frá fjárfestingum | -1,36 ma. | 69,47% |
Reiðufé frá fjármögnun | -19,42 ma. | -266,23% |
Breyting á handbæru fé | 5,49 ma. | -78,50% |
Frjálst peningaflæði | 3,14 ma. | -92,00% |
Um
Sinopharm Group Co., Ltd. is a Chinese pharmaceutical company. The parent company of Sinopharm Group was Sinopharm Industrial Investment, a 51–49 joint venture of state-owned enterprise China National Pharmaceutical Group and civilian-run enterprise Fosun Pharmaceutical.
Its H shares were listed on the Hong Kong Stock Exchange in 2009, with its IPO price of HK$16 per share. Sinopharm Group's subsidiary Sinopharm CNMC and Sinopharm Accord served as the A share counterpart of the company. However, the A share of Sinopharm Group itself was unlisted.
Sinopharm Group was ranked 829th in 2016 Forbes Global 2000 list. Wikipedia
Stofnsett
2003
Vefsvæði
Starfsfólk
108.217
